These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 29045288)

  • 1. Effects of Anti-Inflammatory Medications in Patients With Coronary Artery Disease: A Focus on Losmapimod.
    Tun B; Frishman WH
    Cardiol Rev; 2018; 26(3):152-156. PubMed ID: 29045288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Role of Innovative Anti-Inflammatory Medications in the Prevention of Acute Coronary Syndrome.
    Pashun RA; Frishman WH
    Cardiol Rev; 2015; 23(5):252-60. PubMed ID: 25741604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial.
    O'Donoghue ML; Glaser R; Cavender MA; Aylward PE; Bonaca MP; Budaj A; Davies RY; Dellborg M; Fox KA; Gutierrez JA; Hamm C; Kiss RG; Kovar F; Kuder JF; Im KA; Lepore JJ; Lopez-Sendon JL; Ophuis TO; Parkhomenko A; Shannon JB; Spinar J; Tanguay JF; Ruda M; Steg PG; Theroux P; Wiviott SD; Laws I; Sabatine MS; Morrow DA;
    JAMA; 2016 Apr; 315(15):1591-9. PubMed ID: 27043082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging treatment options to improve cardiovascular outcomes in patients with acute coronary syndrome: focus on losmapimod.
    Kragholm K; Newby LK; Melloni C
    Drug Des Devel Ther; 2015; 9():4279-86. PubMed ID: 26273189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale and design of the LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE trial.
    O'Donoghue ML; Glaser R; Aylward PE; Cavender MA; Crisp A; Fox KA; Laws I; Lopez-Sendon JL; Steg PG; Theroux P; Sabatine MS; Morrow DA
    Am Heart J; 2015 May; 169(5):622-630.e6. PubMed ID: 25965709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of the p38 MAPK inhibitor losmapimod for patients with chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial.
    Watz H; Barnacle H; Hartley BF; Chan R
    Lancet Respir Med; 2014 Jan; 2(1):63-72. PubMed ID: 24461903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The study of LoSmapimod treatment on inflammation and InfarCtSizE (SOLSTICE): design and rationale.
    Melloni C; Sprecher DL; Sarov-Blat L; Patel MR; Heitner JF; Hamm CW; Aylward P; Tanguay JF; DeWinter RJ; Marber MS; Lerman A; Hasselblad V; Granger CB; Newby LK
    Am Heart J; 2012 Nov; 164(5):646-653.e3. PubMed ID: 23137494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of vascular inflammation in coronary artery disease: potential of anti-inflammatory drugs in the prevention of atherothrombosis. Inflammation and anti-inflammatory drugs in coronary artery disease.
    Moreira DM; da Silva RL; Vieira JL; Fattah T; Lueneberg ME; Gottschall CA
    Am J Cardiovasc Drugs; 2015 Feb; 15(1):1-11. PubMed ID: 25369900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological effects of p38 MAPK inhibitor losmapimod does not translate to clinical benefits in COPD.
    Pascoe S; Costa M; Marks-Konczalik J; McKie E; Yang S; Scherbovsky PS
    Respir Med; 2017 Sep; 130():20-26. PubMed ID: 29206629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of antidepressant properties of the p38 MAP kinase inhibitor losmapimod (GW856553) in Major Depressive Disorder: Results from two randomised, placebo-controlled, double-blind, multicentre studies using a Bayesian approach.
    Inamdar A; Merlo-Pich E; Gee M; Makumi C; Mistry P; Robertson J; Steinberg E; Zamuner S; Learned S; Alexander R; Ratti E
    J Psychopharmacol; 2014 Jun; 28(6):570-81. PubMed ID: 24699061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial.
    Newby LK; Marber MS; Melloni C; Sarov-Blat L; Aberle LH; Aylward PE; Cai G; de Winter RJ; Hamm CW; Heitner JF; Kim R; Lerman A; Patel MR; Tanguay JF; Lepore JJ; Al-Khalidi HR; Sprecher DL; Granger CB;
    Lancet; 2014 Sep; 384(9949):1187-95. PubMed ID: 24930728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analgesic efficacy and safety of the novel p38 MAP kinase inhibitor, losmapimod, in patients with neuropathic pain following peripheral nerve injury: a double-blind, placebo-controlled study.
    Ostenfeld T; Krishen A; Lai RY; Bullman J; Baines AJ; Green J; Anand P; Kelly M
    Eur J Pain; 2013 Jul; 17(6):844-57. PubMed ID: 23239139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The p38 mitogen activated protein kinase inhibitor losmapimod in chronic obstructive pulmonary disease patients with systemic inflammation, stratified by fibrinogen: A randomised double-blind placebo-controlled trial.
    Fisk M; Cheriyan J; Mohan D; Forman J; Mäki-Petäjä KM; McEniery CM; Fuld J; Rudd JHF; Hopkinson NS; Lomas DA; Cockcroft JR; Tal-Singer R; Polkey MI; Wilkinson IB
    PLoS One; 2018; 13(3):e0194197. PubMed ID: 29566026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, placebo-controlled trial of the analgesic efficacy and safety of the p38 MAP kinase inhibitor, losmapimod, in patients with neuropathic pain from lumbosacral radiculopathy.
    Ostenfeld T; Krishen A; Lai RY; Bullman J; Green J; Anand P; Scholz J; Kelly M
    Clin J Pain; 2015 Apr; 31(4):283-93. PubMed ID: 25751578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Effectiveness of Anti-Inflammatory Drug Treatments in Coronary Heart Disease Patients: A Systematic Review and Network Meta-Analysis.
    Wudexi I; Shokri E; Abo-Aly M; Shindo K; Abdel-Latif A
    Mediators Inflamm; 2021; 2021():5160728. PubMed ID: 33510581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on the Inflammatory Hypothesis of Coronary Artery Disease.
    Boland J; Long C
    Curr Cardiol Rep; 2021 Jan; 23(2):6. PubMed ID: 33409720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Colchicine in Stable Coronary Artery Disease.
    Fiolet ATL; Nidorf SM; Mosterd A; Cornel JH
    Clin Ther; 2019 Jan; 41(1):30-40. PubMed ID: 30396516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Colchicine in the Management of Acute and Chronic Coronary Artery Disease.
    Bouabdallaoui N; Tardif JC
    Curr Cardiol Rep; 2021 Jul; 23(9):120. PubMed ID: 34269908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Colchicine in Acute Coronary Syndromes.
    Vaidya K; Martínez G; Patel S
    Clin Ther; 2019 Jan; 41(1):11-20. PubMed ID: 30185392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of colchicine on patients with acute and chronic coronary artery disease.
    Madanchi M; Young M; Tersalvi G; Maria Cioffi G; Attinger-Toller A; Cuculi F; Kurmann R; Bossard M
    Eur J Intern Med; 2024 Jul; 125():1-9. PubMed ID: 38238134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.